[go: up one dir, main page]

BRPI0507608A - formulações de anticorpos anti-egfr lìquidas altamente concentradas - Google Patents

formulações de anticorpos anti-egfr lìquidas altamente concentradas

Info

Publication number
BRPI0507608A
BRPI0507608A BRPI0507608-0A BRPI0507608A BRPI0507608A BR PI0507608 A BRPI0507608 A BR PI0507608A BR PI0507608 A BRPI0507608 A BR PI0507608A BR PI0507608 A BRPI0507608 A BR PI0507608A
Authority
BR
Brazil
Prior art keywords
highly concentrated
concentrated liquid
formulations
mab
egfr antibody
Prior art date
Application number
BRPI0507608-0A
Other languages
English (en)
Inventor
Susanne Matheus
Hanns-Christian Mahler
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0507608A publication Critical patent/BRPI0507608A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

FORMULAçõES DE ANTICORPOS ANTI-EGFR LìQUIDAS ALTAMENTE CONCENTRADAS. A presente invenção refere-se a processos para a preparação de formulações líquidas altamente concentradas que compreendem pelo menos um anticorpo antiEGFR e/ou uma de suas variantes e/ou frgmentos, em particular anticorpos monoclonais contra o recptor de EGF, particularmente de preferência de Mab C225 (cetuximab) e mab h425 (EMD 72000), por ultrafiltração. A invenção refere-se adicionalmente a formulações de anticorpos antiEGFR líquidas altamente concentrdas, em particular de anticorpos monoclonais contra o receptor de EGF, particularmente de preferência Mab C225 (cetuximbab ) e Mab (h425 (EMD 72000), E/ou variantes e/ou fragmentos dos mesmos, caracterizada pelo fato de que as formulações líquidas altamente concentradas apresentam um teor de anticorpos antiEGRF de 10- 250, preferencialmente de 50 - 180 mg/ml, particlarmente de preferência de 100 - 150mg/ml, e ao uso dessas formulações.
BRPI0507608-0A 2004-02-12 2005-01-27 formulações de anticorpos anti-egfr lìquidas altamente concentradas BRPI0507608A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54354904P 2004-02-12 2004-02-12
PCT/EP2005/000797 WO2005077414A1 (de) 2004-02-12 2005-01-27 Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern

Publications (1)

Publication Number Publication Date
BRPI0507608A true BRPI0507608A (pt) 2007-07-03

Family

ID=34860438

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507608-0A BRPI0507608A (pt) 2004-02-12 2005-01-27 formulações de anticorpos anti-egfr lìquidas altamente concentradas

Country Status (13)

Country Link
US (2) US20070172475A1 (pt)
EP (1) EP1713502A1 (pt)
JP (1) JP2007522157A (pt)
KR (2) KR20120089307A (pt)
CN (1) CN1953768B (pt)
AR (1) AR047611A1 (pt)
AU (1) AU2005211890B2 (pt)
BR (1) BRPI0507608A (pt)
CA (1) CA2555791A1 (pt)
HK (1) HK1103281A1 (pt)
RU (1) RU2390353C2 (pt)
WO (1) WO2005077414A1 (pt)
ZA (1) ZA200607600B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
IL146480A0 (en) * 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
WO2002011677A2 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
PT1735348E (pt) * 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
DE602005009954D1 (de) 2004-05-12 2008-11-06 Baxter Int Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
WO2005112893A1 (en) 2004-05-12 2005-12-01 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
MXPA06012989A (es) * 2004-05-12 2007-06-12 Baxter Int Microesferas de acidos nucleicos, produccion y suministro de las mismas.
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
CN101663048A (zh) 2005-11-01 2010-03-03 艾博特生物技术有限公司 使用生物标志物诊断强直性脊柱炎的方法和组合物
KR20080110987A (ko) 2006-01-04 2008-12-22 메르크 파텐트 게엠베하 항-ｅｇｆｒ 및 항-ｈｅｒ２ 항체를 이용하는 조합 요법
CA2657517C (en) * 2006-08-04 2016-11-01 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
AU2007300221A1 (en) * 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
KR20080051236A (ko) 2006-12-05 2008-06-11 삼성전자주식회사 엘이디 패키지 및 그 엘이디 패키지를 포함하는 광원유닛및 백라이트 유닛
AU2008205512B2 (en) * 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
WO2008121301A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
JP5744513B2 (ja) 2007-04-17 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 肺送達のための核酸微小粒子
WO2008135380A1 (en) * 2007-05-02 2008-11-13 F. Hoffmann-La Roche Ag Method for stabilizing a protein
EP2165194A4 (en) * 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009117289A2 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
US20110236391A1 (en) * 2008-12-09 2011-09-29 Hanns-Christian Mahler Method for obtaining an excipient-free antibody solution
IN2012DN01965A (pt) * 2009-09-14 2015-08-21 Abbvie Deutschland
JP6055412B2 (ja) 2010-09-17 2016-12-27 バクスアルタ ゲーエムベーハー 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
CN102552875B (zh) * 2010-12-09 2015-05-20 上海国健生物技术研究院 一种双功能vegf受体融合蛋白制剂
CN102153649B (zh) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗egfr人源化抗体l1-h3及其编码基因与应用
KR102103701B1 (ko) 2011-02-11 2020-04-23 메르크 파텐트 게엠베하 전립선암 치료용 항-알파-ｖ 인테그린 항체
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP2015512877A (ja) * 2012-02-22 2015-04-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌を治療するためのクラステリン阻害剤とｅｇｆｒ阻害剤の併用
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2017024152A1 (en) * 2015-08-05 2017-02-09 Dow Global Technologies Llc Compositions and methods for odor control
US10994011B2 (en) * 2015-12-18 2021-05-04 Astellas Pharma Inc. Pharmaceutical composition comprising anti-human TSLP receptor antibody
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
CN108250297B (zh) * 2018-01-23 2021-07-23 上海生物制品研究所有限责任公司 抗egfr抗体、其制法及其应用
TW202027789A (zh) 2018-10-19 2020-08-01 德商馬克專利公司 用於治療大腸直腸癌之阿比特珠單抗(abituzumab)
CN115300623B (zh) * 2021-05-08 2024-06-21 盛禾(中国)生物制药有限公司 抗egfr融合蛋白或其抗原结合片段的组合物及其用途
RU2767044C1 (ru) * 2021-07-19 2022-03-16 Акционерное общество "РАДИОАВИОНИКА" Бортовой ретранслятор комплекса обеспечения радиосвязи разведывательно-ударной системы с беспилотными летательными аппаратами
WO2024010886A2 (en) * 2022-07-07 2024-01-11 Nanostar Pharmaceuticals Ltd. Multilamellar vesicle drug formulation
US12150991B2 (en) 2022-11-07 2024-11-26 Upstream Bio, Inc. Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
JP2005530845A (ja) * 2002-06-21 2005-10-13 アイデック ファーマシューティカルズ コーポレイション 抗体を濃縮するための緩衝化処方物およびその使用方法
CA2450289A1 (en) * 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor

Also Published As

Publication number Publication date
RU2006132466A (ru) 2008-03-20
CN1953768A (zh) 2007-04-25
AU2005211890A1 (en) 2005-08-25
CA2555791A1 (en) 2005-08-25
AU2005211890B2 (en) 2011-07-28
KR101342735B1 (ko) 2013-12-19
US20070172475A1 (en) 2007-07-26
JP2007522157A (ja) 2007-08-09
EP1713502A1 (de) 2006-10-25
AR047611A1 (es) 2006-01-25
CN1953768B (zh) 2010-10-13
WO2005077414A1 (de) 2005-08-25
KR20060121956A (ko) 2006-11-29
US20120076784A1 (en) 2012-03-29
HK1103281A1 (en) 2007-12-14
ZA200607600B (en) 2008-04-30
RU2390353C2 (ru) 2010-05-27
KR20120089307A (ko) 2012-08-09

Similar Documents

Publication Publication Date Title
BRPI0507608A (pt) formulações de anticorpos anti-egfr lìquidas altamente concentradas
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
BRPI0614040B8 (pt) anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
CL2007002800A1 (es) Anticuerpo monoclonal anti-receptor a de interleucina 17 (il-17ra) o fragmento de union a antigeno del mismo; polinucleotido que lo codifica; metodo de preparacion; y metodo para tratar un trastorno influido por la activacion de il-17ra.
EA200870538A1 (ru) Лиофилизированные композиции анти-egfr антител
WO2007124082A3 (en) Buffering agents for biopharmaceutical formulations
BRPI0516299A (pt) formulações farmacêuticas, frascos com uma rolha perfurável por uma seringa, tanques de aço inoxidável, método de tratamento de uma doença ou disfunção, método para redução de deamidação ou agregação de um anticorpo monoclonal, métodos de tratamento de cáncer e método de preparação de uma formulação farmacêutica
BRPI0606148A2 (pt) anticorpos monoclonais neutralizantes contra a sìndrome respiratória aguda grave associada com o coronavìrus
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
RS53752B1 (en) ANTITELO PROTIV ILT7
BRPI0715017A8 (pt) composições e métodos relativos aos anticorpos receptores de glucagon
WO2008121615A3 (en) Antibody formulation
AR069062A1 (es) Anticuerpo anti-hepcidina
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
EP2380592A3 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
UA94576C2 (ru) Выделенное антитело, которое связывается с igf-1r, композиция, которая его содержит, и способы, которые касаются антител
WO2006110214A3 (en) Antibodies against mammalian metapneumovirus
EP2363416A3 (en) Anti-platelet membrane glycoprotein VI monoclonal antibody
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
WO2008060331A3 (en) Antibodies to sars coronavirus
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
CR20120393A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2290 DE 25/11/2014.